Alice T. Shaw

Alice Shaw is a world-leading authority on ALK-rearranged NSCLC who led foundational studies establishing crizotinib and alectinib as transformative therapies for this molecularly defined lung cancer subtype. Her laboratory and clinical research defined mechanisms of resistance to first- and second-generation ALK inhibitors and informed the development of third-generation inhibitors. She now serves as Chief Medical Officer at Novartis Oncology, translating discoveries from bench to global clinical practice. Her contributions have been recognized with numerous national and international awards.